Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings

Johnson & Johnson (JNJ) will begin the earnings season for the drug & biotech sector when it reports its first-quarter 2025 results on April 15. The Zacks Consensus Estimate for first-quarter sales and earnings is pegged at $21.66 billion and$2.57 per share, respectively. The Zacks Consensus Estimate for J&J’s earnings has declined from $10.58 per share to$10.57 per share for 2025, while that for 2026 has declined from $11.07 per share to$11.02 per share over the past 60 days.Find the latest EPS estimate ...